Tetraarsenic tetrasulfide

DB19141InvestigationalSmall molecule

Tetraarsenic tetrasulfide is under investigation in clinical trial NCT05682131 (South China Children Cancer Group - Relapsed-acute Lymphoblastic Leukemia 2022 Protocol).

Mechanism: Pharmacologically active on Telomerase reverse transcriptase
Curator reviewed
Formula / weight: As₄S₄ · 427.93 g/mol (avg)
Also known as: Arsenic disulfide · Arsenic disulphide · Arsenic monosulfide · Arsenic monosulphide · Arsenic sulfide
Code names: C.I. 77085

Resolves to

Compound

UNIIZIK02R2PSDCAS12279-90-2

Clinical / RWD

RxNorm1426938

Structure

InChIKeyXPDICGYEJXYUDW-UHFFFAOYSA-NSMILESS1[As]2S[As]3S[As]2S[As]13

Targets

O14746TERT

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tetraarsenic tetrasulfide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account